Urinary Kallikrein and Blood Pressure –Gender-Different Response to Potassium Supplementation in SHR

E. ODDO V DE LUCA SAROBE R KRMAR R. MARTÍN F IBARRA, E ARRIZURIETA

NEPHRON

Karger

Año: 2008 vol. 108 p. 37 - 45

0028-2766

crease in systolic blood pressure was seen in male SHR: 204.5 8 7.6 versus 173.5 8 7.9 (p ! 0.05); and 164.5 8 4.8 versus 156.8 8 5.5 in female rats (NS) at 12 weeks of age, concomitant with an increase in UKa, particularly in male rats (29.357.6 versus 173.5 8 7.9 (p ! 0.05); and 164.5 8 4.8 versus 156.8 8 5.5 in female rats (NS) at 12 weeks of age, concomitant with an increase in UKa, particularly in male rats (29.358 5.5 in female rats (NS) at 12 weeks of age, concomitant with an increase in UKa, particularly in male rats (29.35 8 1.92 versus 36.54 8 2.61, p ! 0.05). As expected, plasma aldosterone (pg/ml), increased markedly after potassium treatment from 129 8 31.4 in untreated female and male SHR and WKY to 528 8 180.7 in SHR and 473 8 88.4 in WKY (p ! 0.05 in both cases). After potassium supplementation, potassium excretion was significantly correlated with both aldosterone levels and UKa (p ! 0.001 in both cases). No significantly concurrent changes in plasma renin activity were observed, but instead a significant decrease was seen in SHR (p ! 0.01). The potassium blood pressure-lowering effect was blunted by aldosterone receptor antagonist treatment that also decreased UKa from 36.5 8 2.61 to 19.5 8 1.9, particularly in male SHR. No attempt was made in this experimental setting to block kallikrein or kinin receptors. Conclusions:1.92 versus 36.54 8 2.61, p ! 0.05). As expected, plasma aldosterone (pg/ml), increased markedly after potassium treatment from 129 8 31.4 in untreated female and male SHR and WKY to 528 8 180.7 in SHR and 473 8 88.4 in WKY (p ! 0.05 in both cases). After potassium supplementation, potassium excretion was significantly correlated with both aldosterone levels and UKa (p ! 0.001 in both cases). No significantly concurrent changes in plasma renin activity were observed, but instead a significant decrease was seen in SHR (p ! 0.01). The potassium blood pressure-lowering effect was blunted by aldosterone receptor antagonist treatment that also decreased UKa from 36.5 8 2.61 to 19.5 8 1.9, particularly in male SHR. No attempt was made in this experimental setting to block kallikrein or kinin receptors. Conclusions:8 31.4 in untreated female and male SHR and WKY to 528 8 180.7 in SHR and 473 8 88.4 in WKY (p ! 0.05 in both cases). After potassium supplementation, potassium excretion was significantly correlated with both aldosterone levels and UKa (p ! 0.001 in both cases). No significantly concurrent changes in plasma renin activity were observed, but instead a significant decrease was seen in SHR (p ! 0.01). The potassium blood pressure-lowering effect was blunted by aldosterone receptor antagonist treatment that also decreased UKa from 36.5 8 2.61 to 19.5 8 1.9, particularly in male SHR. No attempt was made in this experimental setting to block kallikrein or kinin receptors. Conclusions:8 180.7 in SHR and 473 8 88.4 in WKY (p ! 0.05 in both cases). After potassium supplementation, potassium excretion was significantly correlated with both aldosterone levels and UKa (p ! 0.001 in both cases). No significantly concurrent changes in plasma renin activity were observed, but instead a significant decrease was seen in SHR (p ! 0.01). The potassium blood pressure-lowering effect was blunted by aldosterone receptor antagonist treatment that also decreased UKa from 36.5 8 2.61 to 19.5 8 1.9, particularly in male SHR. No attempt was made in this experimental setting to block kallikrein or kinin receptors. Conclusions:! 0.05 in both cases). After potassium supplementation, potassium excretion was significantly correlated with both aldosterone levels and UKa (p ! 0.001 in both cases). No significantly concurrent changes in plasma renin activity were observed, but instead a significant decrease was seen in SHR (p ! 0.01). The potassium blood pressure-lowering effect was blunted by aldosterone receptor antagonist treatment that also decreased UKa from 36.5 8 2.61 to 19.5 8 1.9, particularly in male SHR. No attempt was made in this experimental setting to block kallikrein or kinin receptors. Conclusions:! 0.001 in both cases). No significantly concurrent changes in plasma renin activity were observed, but instead a significant decrease was seen in SHR (p ! 0.01). The potassium blood pressure-lowering effect was blunted by aldosterone receptor antagonist treatment that also decreased UKa from 36.5 8 2.61 to 19.5 8 1.9, particularly in male SHR. No attempt was made in this experimental setting to block kallikrein or kinin receptors. Conclusions:! 0.01). The potassium blood pressure-lowering effect was blunted by aldosterone receptor antagonist treatment that also decreased UKa from 36.5 8 2.61 to 19.5 8 1.9, particularly in male SHR. No attempt was made in this experimental setting to block kallikrein or kinin receptors. Conclusions:8 2.61 to 19.5 8 1.9, particularly in male SHR. No attempt was made in this experimental setting to block kallikrein or kinin receptors. Conclusions:Conclusions: UKa increases as a consequence of aldosterone stimulation by potassium load since an aldosterone receptor blockade abolishes UKa increment and blood pressure fall. These results further support the hypothesis that the kallikrein kinin system plays a role in blood pressure regulation and they also show a gender different response to potassium load in relation to UKa and blood pressure. Copyright © 2008 S. Karger AG, Basel Key Words Hypertension, sexual dimorphism Sexual dimorphism Potassium supplementation Urinary kallikrein activity, sexual dimorphism Mineralocorticoids Spontaneous hypertensive ratSexual dimorphism Potassium supplementation Urinary kallikrein activity, sexual dimorphism Mineralocorticoids Spontaneous hypertensive ratUrinary kallikrein activity, sexual dimorphism Mineralocorticoids Spontaneous hypertensive ratMineralocorticoids Spontaneous hypertensive rat Abstract Aims: To test whether blood pressure is affected by potassium supplementation which modifies urinary kallikrein (UK) in SHR of either sex, and to elucidate the mechanisms involved. Design: In SHR and WKY blood pressure, renal function and hormonal profile were studied after 1% oral potassium supplementation starting at 4 weeks of age and throughout until 12 weeks of age. Results were compared with those of untreated SHR and WKY of either sex. Results:To test whether blood pressure is affected by potassium supplementation which modifies urinary kallikrein (UK) in SHR of either sex, and to elucidate the mechanisms involved. Design: In SHR and WKY blood pressure, renal function and hormonal profile were studied after 1% oral potassium supplementation starting at 4 weeks of age and throughout until 12 weeks of age. Results were compared with those of untreated SHR and WKY of either sex. Results:Design: In SHR and WKY blood pressure, renal function and hormonal profile were studied after 1% oral potassium supplementation starting at 4 weeks of age and throughout until 12 weeks of age. Results were compared with those of untreated SHR and WKY of either sex. Results:Results: Systolic blood pressure (mm Hg) started to rise in SHR and was significantly different at 6–8 weeks of age: 153.5 8 7.9 versus 100 8 5.6 in female and 157 8 7.7 versus 98.4 8 6.8 in male rats (p ! 0.01). Systolic blood pressure increased progressively in female and male rats reaching 164.5 8 4.8 and 204.5 8 7.6, respectively, at 12 weeks of age. At this time systolic blood pressure was higher in male than in female SHR (p ! 0.01) and UK activity (UKa; nkat/day/100 g body weight) was slightly lower in male SHR. After 1% oral potassium supplementation administered from 4 to 12 weeks of age, a de-8 7.9 versus 100 8 5.6 in female and 157 8 7.7 versus 98.4 8 6.8 in male rats (p ! 0.01). Systolic blood pressure increased progressively in female and male rats reaching 164.5 8 4.8 and 204.5 8 7.6, respectively, at 12 weeks of age. At this time systolic blood pressure was higher in male than in female SHR (p ! 0.01) and UK activity (UKa; nkat/day/100 g body weight) was slightly lower in male SHR. After 1% oral potassium supplementation administered from 4 to 12 weeks of age, a de-8 5.6 in female and 157 8 7.7 versus 98.4 8 6.8 in male rats (p ! 0.01). Systolic blood pressure increased progressively in female and male rats reaching 164.5 8 4.8 and 204.5 8 7.6, respectively, at 12 weeks of age. At this time systolic blood pressure was higher in male than in female SHR (p ! 0.01) and UK activity (UKa; nkat/day/100 g body weight) was slightly lower in male SHR. After 1% oral potassium supplementation administered from 4 to 12 weeks of age, a de-! 0.01). Systolic blood pressure increased progressively in female and male rats reaching 164.5 8 4.8 and 204.5 8 7.6, respectively, at 12 weeks of age. At this time systolic blood pressure was higher in male than in female SHR (p ! 0.01) and UK activity (UKa; nkat/day/100 g body weight) was slightly lower in male SHR. After 1% oral potassium supplementation administered from 4 to 12 weeks of age, a de-8 4.8 and 204.5 8 7.6, respectively, at 12 weeks of age. At this time systolic blood pressure was higher in male than in female SHR (p ! 0.01) and UK activity (UKa; nkat/day/100 g body weight) was slightly lower in male SHR. After 1% oral potassium supplementation administered from 4 to 12 weeks of age, a de-8 7.6, respectively, at 12 weeks of age. At this time systolic blood pressure was higher in male than in female SHR (p ! 0.01) and UK activity (UKa; nkat/day/100 g body weight) was slightly lower in male SHR. After 1% oral potassium supplementation administered from 4 to 12 weeks of age, a de-! 0.01) and UK activity (UKa; nkat/day/100 g body weight) was slightly lower in male SHR. After 1% oral potassium supplementation administered from 4 to 12 weeks of age, a de-